Genentech: Cyrus Khojasteh | Senior Director and Senior Principal Scientist (Technology), Drug Metabolism & Pharmacokinetics

Scientists / Our Scientists

"My ability to contribute to the discovery of safe and efficacious drugs to treat important unmet medical conditions is what keeps me inspired."

Years at Genentech

Publications

Awards & Honors

I joined Genentech in 2000 and had the opportunity to contribute in building the state-of-the-art organization that supports small molecule and antibody-drug conjugates in both discovery and development. I work with a very talented team of scientists that are passionate about discovering the next great medicine. This is a great place where great scientists ask fundamental questions and go to the lab to test their hypothesis.

Featured Publication

A probabilistic method to report predictions from a human liver microsomes stability QSAR model: a practical tool for drug discovery.

Journal of Computer-Aided Molecular Design 2015, 29(4): 327-38.

Aliagas I, Gobbi A, Heffron T, Lee ML, Ortwine DF, Zak M, Khojasteh SC.

View Abstract

My research focus is to figure out the molecular mechanism for metabolism. How and where does a drug candidate is converted to metabolite(s). This is not only focused on cytochrome P450 enzymes, which are very important, but also to all kinds of enzyme systems that are involved in oxidation, reduction, hydrolysis and conjugation. I am also interested in soft spots in the drug candidates and how the molecule could be changed to minimize metabolic rates. I am also interested in the consequence of metabolism, with asking if we are making reactive metabolites that can covalently modify cellular macromolecules.

Characterization of Tissue Distribution, Catabolism, and Elimination of an Anti-Staphylococcus aureus THIOMAB Antibody-Antibiotic Conjugate in Rats

Drug Metabolism and Disposition,

Hao Cai; Victor Yip; Violet Lee; Sylvia Wong; Ola Saad; Shuguang Ma; Nina Ljumanovic; S Cyrus Khojasteh; Amrita Kamath; Ben-Quan Shen

Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody-Drug Conjugates

Journal of Medicinal Chemistry,

Leanna Staben; Jinhua Chen; Josefa Dela Cruz-Chuh; Geoff Del Rosario; Mary Ann Go; Jun Guo; S Cyrus Khojasteh; Kathy Kozak; Ginny Li; Carl Ng; Gail D. Lewis Phillips; Thomas Pillow; Rebecca K. Rowntree; John Wai; Binqing Wei; Keyang Xu; Zijin Xu; Shang-Fan Yu; Donglu Zhang; Peter Dragovich

Strategies to Mitigate the Bioactivation of Aryl Amines

Chemical Research in Toxicology, ISSN: 15205010

Chenghong Zhang; James Crawford; Matthew L. Landry; Huifen Chen; Jane Kenny; S Cyrus Khojasteh; Wendy Lee; Shuguang Ma; Wendy B. Young

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Cyrus Khojasteh

Senior Director and Senior Principal Scientist (Technology), Drug Metabolism & Pharmacokinetics

Featured Publication

A probabilistic method to report predictions from a human liver microsomes stability QSAR model: a practical tool for drug discovery.